Human Microbiome Market Size, Share & Industry Analysis, By Product (Probiotics, Prebiotics, Symbiotics, Others), By Application (Therapeutics, Diagnostics, Nutrition and Dietics, Others), By Distribution Channel (Retail Pharmacies, Online Pharmacies, Supermarkets and Hypermarket) And Regional Forecast, 2024-2032

Human microbiome is the collection of microorganisms that reside on and within our body. The Human Microbiome Project, was initiated by United States National Institutes of Health (NIH) to improve understanding of the microbial flora involved in human health and disease.

The global human microbiome market shows promising growth which can be attributed to applications of microbiome technology in human health. Major applications of microbiome includes predictive, preventive and personalized medicine. Moreover, strategic collaborations along with mergers and acquisitions in the industry are also promoting market growth. For instance, in February 2021, International Flavors and Fragrances announced merger with DuPont’s Nutrition and Biosciences division. Furthermore, entry of large capital companies into microbiome modulators industry such as Johnson & Johnson Services, Inc. are likely to improve the market for human microbiome industry. Johnson & Johnson Services, Inc.

Key factors driving the human microbiome market are increasing applications of microbiome in human healthcare such as dietary supplementation and skin therapy. Moreover, technological advancements in microbiome industry include Next Generation Sequencing based genetic testing and high throughput microbiome characterization which may promote microbiome industry growth. Furthermore, recent entry of major food industry players such as DuPont entering the microbiome industry may turn out to push the global market size to grow further. 

Key Market Driver -

Increase in applications of microbiome based products in human health, technological advancements in microbiome industry.

Key Market Restraint -

– Lack of gold standards and stringent regulation in the industry, inadequate knowledge about human microbiome products

Market Segmentation:

Globally, the human microbiome market can be segmented on the basis of product, application, research technology, end user and region. Based on the product, the market can be segmented into probiotics, prebiotics, symbiotics, others. Based on application, market can be segmented into therapeutics, diagnostics, nutrition and dietics and others. On the basis of distribution channel, market can be segmented into retail pharmacies, online pharmacies, supermarkets & hypermarkets. Based on geography the market is segmented by North America, Europe, Asia pacific, Latin America and Middle east- Africa.

Key Players Covered:

Some of the major companies that are operating in the human microbiome market are 4D Pharma, Series Therapeutics, Second Genome, Enterome, MicroBiome Therapeutics LLC, Rebiotix Inc., Yakult Honsha Co. Ltd., Osel Inc., Vedanta Biosciences Inc., Metabiomics Corporate, Synthetic Biologics Inc., DuPont, BiomX Ltd., Pylum other prominent players.

Key Insights:

• Key Industry Trends


• Technological Advancements in human microbiome


• New Product Launches


• Key Industry Developments Mergers, Acquisitions, And Collaborations

Regional Analysis:

Geographically, the human microbiome market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is anticipated to account for majority of the share in global human microbiome market. The dominance of the region is attributable to increasing prevalence of lifestyle disorders and advancements in next generation sequencing. For instance, Illumina Inc., a leading player in the U.S., states that the emergence of next-generation sequencing enables several high-profile collaborative projects such as the Human Microbiome Project and MetaHIT. These projects have published a wide range of data on the human microbiome using Next Generation Sequencing as a foundational tool.

Europe is expected to grow in market share during the forecast period attributed to comprehensive research and development of new applications of human microbiome. For instance, in March 2020, according to NCBI, new microbiome projects such as ONCOBIOME, MICROB-predict and GEMMA are focused on oncology, mapping of human microbiota and autism spectrum disorders respectively which are likely to fuel the market growth in this region.

Moreover, Asia Pacific is expected to grow during the forecast period owing to the increasing establishment of institutions working on microbiome and ancillary fields. For instance, in March 2020, the Institute of Genomics and Integrative Biology (IGIB) which is a CSIR institute, is spearheading the Genomics for Public Health in India, also called IndiGen project. It is planning to enroll 20,000 Indians for whole genome sequencing in the next couple of years to build a larger database. The data will be important for building the knowhow, baseline data and indigenous capacity in the emerging area of precision medicine.

Furthermore, increasing prevalence of disorders affecting quality of life and growth in the healthcare sector may encourage market growth. The market in Latin America and the Middle East & Africa are at a budding stage currently due to slower adoption rates of upcoming advancements and generally follow trends of more relatively matured markets.

To gain extensive insights into the market, Request for Customization

Segmentation

Global Human Microbiome Industry Developments

• In July 2021, Seres Therapeutics Inc. entered into an agreement with Nestlé Health Science to jointly commercialize SER-109, an investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection (CDI), in the United States (U.S.) and Canada. If approved, SER-109 would become the first-ever FDA-approved microbiome therapeutic.


• In July 2021, 4D pharma plc, a pharmaceutical company leading the development of Live Bio therapeutic, announced the publication of pre-clinical research relating to its second-generation immuno-oncology LBP MRx1299 improving the activity of CAR-T. It demonstrates the ability of the bacterium Megasphaera massiliensis or its short chain fatty acid (SCFA) metabolite pentanoate to enhance the anti-tumour activity of cytotoxic T lymphocytes (CTL) and CAR-T therapies in animal models of cancer, resulting in better tumour clearance.


• In Nov 2017, AvidBiotics announced to split their company into two biotechnology companies. One company, Xyphos Inc., will be focused on immuno-oncology applications and the other company, Pylum Biosciences, Inc., on antibacterial proteins for microbiota management and drug-resistant bacteria.